Evidence map›Paper›PMID 38049415›Full record

ArticleCell death & disease2023

Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.

De-Pei Yin, Huanle Zhang, Hua Teng, Dan Zhang, Peipei Chen, Lixiao Xie, Ji-Sheng Liu

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

De-Pei Yin *Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Huanle Zhang *Department of Radiotherapy, Suzhou Ninth People's Hospital, Suzhou, China.
Hua Teng *Department of Otorhinolaryngology Head and Neck Surgery, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Dan Zhang *Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Peipei ChenDepartment of Otorhinolaryngology Head and Neck Surgery, Children's Hospital of Soochow University, Suzhou, China. chenpp1123@163.com.
Lixiao XieDepartment of Otorhinolaryngology Head and Neck Surgery, Children's Hospital of Soochow University, Suzhou, China. xielixiaoxielixiao@163.com.
Ji-Sheng LiuDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. sdfyyljs@sina.com.ORCID 0000-0001-8452-4917
Soochow University · CNJiangsu Province Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82002850
6 · The paper itself

Abstract

The current study tested the expression and potential functions of Gαi1 in nasopharyngeal carcinoma (NPC). The Cancer Genome Atlas (TCGA) database results demonstrate that Gαi1 transcripts' number in NPC tissues is significantly higher than that in the normal nasal epithelial tissues. Its overexpression correlates with poor survival in certain NPC patients. Moreover, Gαi1 is significantly upregulated in NPC tissues of local primary patients and in different primary human NPC cells. Whereas its expression is relatively low in cancer-surrounding normal tissues and in primary nasal epithelial cells. Genetic silencing (via shRNA strategy) or knockout (via CRISPR-sgRNA method) of Gαi1 substantially suppressed viability, proliferation, cell cycle progression, and migration in primary NPC cells, causing significant caspase-apoptosis activation. Contrarily, ectopic Gαi1 expression exerted pro-tumorigenic activity and strengthened cell proliferation and migration in primary NPC cells. Gαi1 is important for Akt-mTOR activation in NPC cells. Akt-S6K phosphorylation was downregulated after Gαi1 shRNA or KO in primary NPC cells, but strengthened following Gαi1 overexpression. In Gαi1-silenced primary NPC cells, a S473D constitutively-active mutant Akt1 (caAkt1) restored Akt-S6K phosphorylation and ameliorated Gαi1 shRNA-induced proliferation inhibition, migration reduction and apoptosis. Bioinformatics analyses proposed zinc finger protein 384 (ZNF384) as a potential transcription factor of Gαi1. In primary NPC cells, ZNF384 shRNA or knockout (via CRISPR-sgRNA method) decreased Gαi1 mRNA and protein expression, whereas ZNF384 overexpression upregulated it. Importantly, there was an increased binding between ZNF384 protein and the Gαi1 promoter in human NPC tissues and different NPC cells. In vivo studies showed that intratumoral injection of Gαi1-shRNA-expressing adeno-associated virus (AAV) impeded subcutaneous NPC xenograft growth in nude mice. Gαi1 downregulation, Akt-mTOR inactivation, and apoptosis induction were detected in Gαi1-silenced NPC xenograft tissues. Gαi1 KO also effectively inhibited the growth of NPC xenografts in nude mice. Together, overexpressed Gαi1 exerts pro-tumorigenic activity in NPC possibly by promoting Akt-mTOR activation.

Indexed as

GTP-Binding Protein alpha Subunits, Gi-GoNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAnimalsCell Line, TumorCell ProliferationHumansMiceMice, NudeProto-Oncogene Proteins c-aktRNA, Guide, CRISPR-Cas SystemsRNA, Small InterferingSignal TransductionTOR Serine-Threonine KinasesTranscription FactorsGNAI1 protein, humanGTP-Binding Protein alpha Subunits, Gi-GoProto-Oncogene Proteins c-aktRNA, Guide, CRISPR-Cas SystemsRNA, Small InterferingTOR Serine-Threonine KinasesTranscription Factors

Identifiers

PMID38049415
PMCPMC10696052
OpenAlexW4389302976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.